Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Early Immune Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HCT) with Post-Transplant Cyclophosphamide (PTCY) Does Not Improve Overall Survival Compared to Matched Unrelated Donor HCT Recipients Receiving Thymoglobulin Prophylaxis (ATG)

Yasser Khaled, MD, Joshua Boss, RN, OCN, BMTCN, Poojitha Valasareddy, MD, Arnel Pallera, MD, Robert Johnson, MD, Deniscer Peeler, LPN, Jason C. Chandler, MD, Joel Gradowski, MD

Blood (2019) 134 (Supplement_1): 5676.

https://doi.org/10.1182/blood-2019-131954

Published: 2019

Journal Articles

T-Cell Replete Peripheral Blood Haploidentical Transplant Using Immunogenic Dose of Cyclophosphamide with Fludarabine and Melphalan Results in Enhanced Cytokine Release Syndrome (CRS) with Robust Immune Recovery and Low Relapse Rates

Yasser Khaled, MD, Jason C. Chandler, MD, Joshua Boss, RN, OCN, Arnel Pallera, MD, Michael G. Martin, MD, Robert Bradley, MD, Robert Johnson, MD

Blood (2017) 130 (Supplement 1): 1934.

https://doi.org/10.1182/blood.V130.Suppl_1.1934.1934

Published: 2017

Journal Articles

Construction of An Outpatient Erythrocytapheresis Program for Pediatric Patients with Sickle Cell Disease

Paulette Bryant, MD, Richard Parmley, MD, Christine Bolen, MD, Theresa Sunderland, MD, Robert Johnson, MD, Jennifer Weisner, PNP, Karen Nishioka, BSN, Karen Roberts, RN, Richard Towell, RN, Jodi P. Strong, MBA, Evelyn Lockhart, MD, Mark Mogul, MD

Blood (2008) 112 (11): 4067.

https://doi.org/10.1182/blood.V112.11.4067.4067

Published: 2008

Journal Articles

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

Jeffrey Lancet, MD, Maria R. Baer, MD, Ivana Gojo, MD, M. Burton, M. Quinn, S.M. Tighe, Kapil Bhalla, MD, K. Kersey, S. Wells, Z. Zhong, PhD, B. Sadler, Maher Albitar, MD, Robert Johnson, MD, PhD, Alison Hannah, MBBS

Blood (2006) 108 (11): 1961.

https://doi.org/10.1182/blood.V108.11.1961.1961

Published: 2006

Journal Articles

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).

Paul Richardson, MD, Asher Alban Chanan-Khan, MD, Sagar Lonial, MD, Amrita Krishnan, MD, Melissa Alsina, MD, Michael Carroll, MD, Karen Adler, G. Cropp, C. Mitsiades, MD, Robert Johnson, MD, PhD, Alison Hannah, MBBS, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 406.

https://doi.org/10.1182/blood.V108.11.406.406

Published: 2006

Journal Articles

Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.

Constantine S. Mitsiades, MD, PhD, Nicholas Mitsiades, MD, PhD, Melissa Rooney, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, PhD, Robert Johnson, MD, Alison Hannah, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2404.

https://doi.org/10.1182/blood.V104.11.2404.2404

Published: 2004

NARROW

Early Immune Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HCT) with Post-Transplant Cyclophosphamide (PTCY) Does Not Improve Overall Survival Compared to Matched Unrelated Donor HCT Recipients Receiving Thymoglobulin Prophylaxis (ATG)

T-Cell Replete Peripheral Blood Haploidentical Transplant Using Immunogenic Dose of Cyclophosphamide with Fludarabine and Melphalan Results in Enhanced Cytokine Release Syndrome (CRS) with Robust Immune Recovery and Low Relapse Rates

Construction of An Outpatient Erythrocytapheresis Program for Pediatric Patients with Sickle Cell Disease

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).

Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.

Email alerts

ASH Publications

American Society of Hematology

Early Immune Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HCT) with Post-Transplant Cyclophosphamide (PTCY) Does Not Improve Overall Survival Compared to Matched Unrelated Donor HCT Recipients Receiving Thymoglobulin Prophylaxis (ATG)

T-Cell Replete Peripheral Blood Haploidentical Transplant Using Immunogenic Dose of Cyclophosphamide with Fludarabine and Melphalan Results in Enhanced Cytokine Release Syndrome (CRS) with Robust Immune Recovery and Low Relapse Rates

Construction of An Outpatient Erythrocytapheresis Program for Pediatric Patients with Sickle Cell Disease

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).

Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only